Mark Tarnopolsky

Dr Mark Tarnopolsky

Co-Applicant

Professor of Pediatrics and Medicine, Director of Neuromuscular and Neurometabolic Clinic, McMaster University Medical Center

CEO/CSO Exerkine Corporation


NMD4C Involvement: Pillar 1: Preclinical Science

Email Mark

Research Interests: Mitochondrial disease, Neurogenetic diagnostics, Neurometabolic disorders, MD therapeutics, Aging/sarcopenia, Obesity

Academic web profile
Google Scholar profile

Biography

Dr. Tarnopolsky is a neuromuscular and neurometabolic clinician-scientist who received an MD and PhD (Cell Biology and Metabolism) from McMaster University.  He currently holds an endowed chair from McMaster Children’s Hospital Foundation in the area of neuromuscular and neurometabolic genetic disorders and follows over 1500 patients with myopathies, mitochondrial disorders and other neurogenetic disorders. He has published over 500 peer reviewed papers and has an h-index of 142.  His research focuses on pharmacological, nutraceutical and exercise therapies for neuromuscular and neurometabolic disorders, aging, obesity and other disorders that affect the mitochondria and muscle function.  He is the founder, CEO and CSO of Exerkine Corporation which is a bio-technology/nutraceutical company developing therapies for aging, obesity, muscular dystrophy and mitochondrial disorders.


Recent Publications

Karaa, A, Bertini, E, Carelli, V, Cohen, B, Ennes, GM, Falk, MJ et al.. Genotype-specific effects of elamipretide in patients with primary mitochondrial myopathy: a post hoc analysis of the MMPOWER-3 trial. Orphanet J Rare Dis. 2024.19 (1)431 PMID:39574155

Kishnani, PS, Byrne, BJ, Claeys, KG, DĂ­az-Manera, J, Dimachkie, MM, Kushlaf, H et al.. Switching treatment to cipaglucosidase alfa plus miglustat positively affects patient-reported outcome measures in patients with late-onset Pompe disease. J Patient Rep Outcomes. 2024.8 (1)132 PMID:39535661

McMillan, HJ, Gonorazky, H, Campbell, C, Chrestian, N, Crone, M, Dowling, JJ et al.. Equitable Access to Disease-Modifying Therapies for Canadian Children with SMA and Four SMN2 Copies. Can J Neurol Sci. 2024. 1-3 PMID:39534980

Al-Tawari, J, Tarnopolsky, MA, Burneo, JG, Budhram, A. Lack of Comprehensive Neural Antibody Testing: A Contributor to Diagnostic Delay in Autoimmune Encephalitis. Can J Neurol Sci. 2024. 1-4 PMID:39494937

Mak, G, Tarnopolsky, M, Lu, JQ. Secondary mitochondrial dysfunction across the spectrum of hereditary and acquired muscle disorders. Mitochondrion. 2024.78 101945 PMID:39134108

Brady, L, Yadav, R, Edmondson, AC, Tarnopolsky, M. Missense variant in PIGM associated with severe cystic encephalomalacia and portal vein thrombosis: Phenotypic and genotypic expansion of the glycosylphosphatidylinositol biosynthesis defect-1 (GPIBD1). Am J Med Genet A. 2024.194 (12)e63833 PMID:39119839

Mak, G, Tarnopolsky, M, Lu, JQ. A case of mixed hereditary gelsolin amyloidosis and hydroxychloroquine induced myopathy. Acta Neurol Belg. 2024.124 (6)2099-2101 PMID:39078605

Martin, G, Al-Sajee, D, Gingrich, M, Chattha, R, Akcan, M, Monaco, CMF et al.. Skeletal muscle mitochondrial morphology negatively affected in mice lacking Xin. Biochem Cell Biol. 2024.102 (5)373-384 PMID:38843556

Foglia, SD, Adams, FC, Ramdeo, KR, Drapeau, CC, Turco, CV, Tarnopolsky, M et al.. Investigating the effects of dopamine on short- and long-latency afferent inhibition. J Physiol. 2024.602 (10)2253-2264 PMID:38638084

Marshall, AE, Brady, L, Yeh, E, Mears, AJ, Lacaria, M, Chakraborty, P et al.. Next generation sequencing reveals novel compound heterozygous deletions in NDUFAF2 in a child with mitochondrial complex I deficiency, nuclear type 10. Am J Med Genet A. 2024.194 (7)e63590 PMID:38477541

See more on PubMed